1.16

4.92% -0.06

Celularity Inc (CELU)

Overview News Price History Option Chain Financials Discussions Forecast

Celularity Inc stock is traded at $1.16, with a volume of 117.16K. It is down -4.92% in the last 24 hours and down -53.04% over the past month. Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.

Previous Close:

$1.22

Open:

$1.22

24h Volume:

117.16K

Relative Volume:

0.68

Market Cap:

$29.05M

Revenue:

$48.20M

Net Income/Loss:

$-35.05M

P/E Ratio:

-0.7401

EPS:

-1.5673

Net Cash Flow:

$-13.02M

1W Performance:

-30.95%

1M Performance:

-53.04%

6M Performance:

-59.72%

1Y Performance:

-70.36%

1-Day Range:

$1.15

$1.245

1-Week Range:

$1.15

$1.72

52-Week Range:

$1.15

$7.97

Celularity Inc Stock (CELU) Company Profile

Name

Celularity Inc

Sector

Healthcare (1189)

Industry

Biotechnology (675)

Phone

(908) 768-2170

Address

170 PARK AVE, FLORHAM PARK

Employee

120

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

CELU's Discussions on Twitter

Compare CELU with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CELU Celularity Inc	1.155	29.05M	48.20M	-35.05M	-13.02M	-1.5673
VRTX Vertex Pharmaceuticals Inc	477.45	121.85B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	698.03	76.83B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	618.58	37.96B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	242.53	30.69B	2.25B	-278.16M	-42.59M	-2.17
ONC Beone Medicines Ltd Adr	269.23	29.71B	3.32B	-860.46M	-1.04B	-8.32

Celularity Inc Stock (CELU) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-30-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Dec-22-22	Downgrade	Oppenheimer	Outperform → Perform
Jun-22-22	Initiated	H.C. Wainwright	Buy
Apr-06-22	Downgrade	Truist	Buy → Hold
Jan-28-22	Initiated	Oppenheimer	Outperform
Nov-24-21	Initiated	Morgan Stanley	Equal-Weight

View All

Celularity Inc Stock (CELU) Latest News

Feb 27, 2025

CELU Stock Touches 52-Week Low at $1.29 Amid Market Challenges By Investing.com - Investing.com South Africa

Feb 27, 2025

Feb 26, 2025

Celularity receives FDA TRG recommendation letters for Natalin, Acelagraft - MSN

Feb 26, 2025

Celularity Enters Strategic Collaboration Agreement with BlueSphere Bio to Support Cell Therapy Manufacturing - Defense World

Feb 26, 2025

Feb 25, 2025

Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products - The Manila Times

Feb 25, 2025

Celularity Secures Crucial FDA Pathway for Wound Care ProductsCan They Capture Share of $810M Market? - StockTitan

Feb 25, 2025

Feb 24, 2025

Celularity inks manufacturing deal with BlueSphere Bio By Investing.com - Investing.com Australia

Feb 24, 2025

Celularity inks manufacturing deal with BlueSphere Bio - Investing.com

Feb 24, 2025

Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company - The Manila Times

Feb 24, 2025

Can This New Cell Therapy Manufacturing Deal Transform Celularity's Revenue Potential? - StockTitan

Feb 24, 2025

Feb 21, 2025

Celularity Inc.'s (NASDAQ:CELU) Business And Shares Still Trailing The Industry - Simply Wall St

Feb 21, 2025

Feb 20, 2025

Celularity Inc. Extends Loan Agreements with Resorts World Inc and C.V. Starr & Co. - Defense World

Feb 20, 2025

Feb 13, 2025

SEC Form FWP filed by Celularity Inc. - Quantisnow

Feb 13, 2025

Feb 10, 2025